ZYBERNO
Stock Report
Updated Sep 1, 2026

Neuphoria Therapeutics Inc. (NEUP)

Healthcare • NASDAQ

$3.76

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
27.0/100
POOR BUSINESS
Neuphoria Therapeutics Inc. (NEUP) scores 27/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-53.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-106.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Neuphoria Therapeutics Inc. (NEUP) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.76
Market Cap:$20.35M

Valuation Multiples (3)

P/B Ratio:0.69x
P/S Ratio:1.30x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$990.83K

Price Action & Momentum (1)

% of 52-Week High:17.6%
B. Profitability Assessment

Return Metrics (5)

ROA:-38.1%
Reinvestment Rate:6.2%
Fundamental Growth Rate (g):-6.6%

Margin Analysis (1)

Ebitda Margin:-87.3%

Yield Metrics (2)

Earnings Yield:-$177.52
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:14.31x
Quick Ratio:14.31x
Cash Ratio:12.85x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:20,144,599.00
Cash And Cash Equivalents:19,440,655.00
Long Term Debt:$0.00
Net Debt:-$19.36M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$15.65M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$14.32M

Bottom Line Performance (3)

-$12.14M
Income Before Tax:-$12.56M
Ebitda Ttm:-13,655,043.00

Operating Expenses (5)

Operating Expenses:14,967,381.00
R And D Expense:9,005,097.00
Sga Expense:8,054,049.00
Income Tax Expense:-$421.97K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:60.0%
Sga To Revenue Percentage:53.7%
Ebitda Margin:-87.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$34.81M
Current Assets:$21.66M
Ppe Net:2,573.00
Goodwill:8,843,549.00
Intangible Assets:$4.31M

Liability Structure (4)

Total Liabilities:5,385,256.00
Current Liabilities:1,513,309.00
Long Term Debt:$0.00
Short Term Debt:$85.21K

Equity & Capital (3)

Equity:$29.42M
Retained Earnings:-$186.89M
Common Stock:30,000,000.00

Working Capital Items (3)

Accounts Receivable:1,605,340.00
Inventory:0.00
Accounts Payable:627,185.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:93,701.00
C. Cash Flow Analysis

Operating Activities (2)

$77.23K$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$14.66M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,253,615.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-6.87
-$6.87
Earnings Per Share Ttm:-$2.24

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.89
Operating Cash Flow Per Share:$0.01

Book Value & Capital (2)

Book Value Per Share:$5.44
Cash Per Share:3.59

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.49x
Working Capital Turnover Ttm:0.78x

Receivables Management (2)

Receivables Turnover Ttm:9.75x
Days Sales Outstanding Ttm:37.44

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:14.63
Cash Conversion Cycle:-976.19
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:50.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:6.2%
Fundamental Growth Rate (g):-6.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):32.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:NEUP
Company Name:Neuphoria Therapeutics Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.41M
Shares Outstanding Basic:5.41M
Shares Outstanding Diluted:5.41M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 10:09:59 UTC
Data Timestamp:2026-08-21T00:57:31.328418
Scroll to Top